25 XP   0   0   10

Prelude Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Prelude Therapeutics Inc together

PenkeI guess you are interested in Prelude Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Prelude Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Prelude Therapeutics Inc

I send you an email if I find something interesting about Prelude Therapeutics Inc.

Quick analysis of Prelude Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Prelude Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.32
Expected worth in 1 year
$4.55
How sure are you?
23.5%

+ What do you gain per year?

Total Gains per Share
$0.24
Return On Investment
6.2%

For what price can you sell your share?

Current Price per Share
$3.84
Expected price per share
$1.66 - $6.025
How sure are you?
50%

1. Valuation of Prelude Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$3.84

Intrinsic Value Per Share

$-18.43 - $-21.37

Total Value Per Share

$-14.11 - $-17.05

2. Growth of Prelude Therapeutics Inc (5 min.)




Is Prelude Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$237m$228.8m-$699k-0.3%

How much money is Prelude Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$30.1m-$26.1m-$4m-13.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Prelude Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#218 / 1007

Most Revenue
#742 / 1007

Most Profit
#791 / 1007

Most Efficient
#180 / 1007

What can you expect buying and holding a share of Prelude Therapeutics Inc? (5 min.)

Welcome investor! Prelude Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Prelude Therapeutics Inc.

What can you expect buying and holding a share of Prelude Therapeutics Inc?

First you should know what it really means to hold a share of Prelude Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Prelude Therapeutics Inc is $3.84. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Prelude Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Prelude Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.32. Based on the TTM, the Book Value Change Per Share is $0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Prelude Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.60-15.7%-0.54-14.2%-0.61-15.8%-0.51-13.2%-0.51-13.2%
Usd Book Value Change Per Share0.8020.7%0.061.5%-0.52-13.6%0.256.6%0.256.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.8020.7%0.061.5%-0.52-13.6%0.256.6%0.256.6%
Usd Price Per Share4.27-4.39-6.19-15.27-15.27-
Price to Earnings Ratio-1.77--2.00--2.54--7.50--7.50-
Price-to-Total Gains Ratio5.37--1.69--11.86--24.75--24.75-
Price to Book Ratio0.99-1.10-1.30-2.67-2.67-
Price-to-Total Gains Ratio5.37--1.69--11.86--24.75--24.75-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.84
Number of shares260
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.060.25
Usd Total Gains Per Share0.060.25
Gains per Quarter (260 shares)15.4266.03
Gains per Year (260 shares)61.69264.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1062520264254
201231140528518
301851760792782
40247238010571046
50308300013211310
60370362015851574
70432424018491838
80494486021132102
90555548023772366
100617610026412630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%4.012.01.023.5%4.012.01.023.5%4.012.01.023.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%4.012.01.023.5%4.012.01.023.5%4.012.01.023.5%

Fundamentals of Prelude Therapeutics Inc

About Prelude Therapeutics Inc

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Fundamental data was last updated by Penke on 2024-04-12 15:41:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Prelude Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Prelude Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Prelude Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Prelude Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.4%+282.4%
5Y--434.0%+434.0%
10Y--584.8%+584.8%
1.1.2. Return on Assets

Shows how efficient Prelude Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Prelude Therapeutics Inc to the Biotechnology industry mean.
  • -11.9% Return on Assets means that Prelude Therapeutics Inc generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Prelude Therapeutics Inc:

  • The MRQ is -11.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.9%TTM-12.0%+0.1%
TTM-12.0%YOY-10.4%-1.6%
TTM-12.0%5Y-15.5%+3.5%
5Y-15.5%10Y-15.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.9%-13.2%+1.3%
TTM-12.0%-12.7%+0.7%
YOY-10.4%-11.5%+1.1%
5Y-15.5%-13.8%-1.7%
10Y-15.5%-15.5%+0.0%
1.1.3. Return on Equity

Shows how efficient Prelude Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Prelude Therapeutics Inc to the Biotechnology industry mean.
  • -14.0% Return on Equity means Prelude Therapeutics Inc generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Prelude Therapeutics Inc:

  • The MRQ is -14.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.0%TTM-13.4%-0.6%
TTM-13.4%YOY-11.4%-1.9%
TTM-13.4%5Y-8.9%-4.5%
5Y-8.9%10Y-8.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.0%-16.7%+2.7%
TTM-13.4%-15.9%+2.5%
YOY-11.4%-14.7%+3.3%
5Y-8.9%-19.2%+10.3%
10Y-8.9%-20.0%+11.1%

1.2. Operating Efficiency of Prelude Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Prelude Therapeutics Inc is operating .

  • Measures how much profit Prelude Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Prelude Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Prelude Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--291.9%+291.9%
5Y--485.6%+485.6%
10Y--610.8%+610.8%
1.2.2. Operating Ratio

Measures how efficient Prelude Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Prelude Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.791-3.791
5Y-5.675-5.675
10Y-7.558-7.558

1.3. Liquidity of Prelude Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Prelude Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.79 means the company has $10.79 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Prelude Therapeutics Inc:

  • The MRQ is 10.792. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.686. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.792TTM12.686-1.893
TTM12.686YOY13.117-0.431
TTM12.6865Y14.321-1.635
5Y14.32110Y14.3210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.7923.877+6.915
TTM12.6864.178+8.508
YOY13.1175.343+7.774
5Y14.3216.135+8.186
10Y14.3216.468+7.853
1.3.2. Quick Ratio

Measures if Prelude Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Prelude Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 20.18 means the company can pay off $20.18 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Prelude Therapeutics Inc:

  • The MRQ is 20.183. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 23.740. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ20.183TTM23.740-3.557
TTM23.740YOY23.354+0.386
TTM23.7405Y20.482+3.258
5Y20.48210Y20.4820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.1833.514+16.669
TTM23.7403.998+19.742
YOY23.3545.380+17.974
5Y20.4826.135+14.347
10Y20.4826.434+14.048

1.4. Solvency of Prelude Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Prelude Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Prelude Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Prelude Therapeutics Inc assets are financed with 14.6% credit (debt) and the remaining percentage (100% - 14.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Prelude Therapeutics Inc:

  • The MRQ is 0.146. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.102. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.146TTM0.102+0.044
TTM0.102YOY0.088+0.013
TTM0.1025Y0.629-0.528
5Y0.62910Y0.6290.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1460.339-0.193
TTM0.1020.336-0.234
YOY0.0880.271-0.183
5Y0.6290.368+0.261
10Y0.6290.388+0.241
1.4.2. Debt to Equity Ratio

Measures if Prelude Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Prelude Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.1% means that company has $0.17 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Prelude Therapeutics Inc:

  • The MRQ is 0.171. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.115. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.171TTM0.115+0.057
TTM0.115YOY0.098+0.017
TTM0.1155Y0.069+0.046
5Y0.06910Y0.0690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1710.388-0.217
TTM0.1150.403-0.288
YOY0.0980.340-0.242
5Y0.0690.430-0.361
10Y0.0690.463-0.394

2. Market Valuation of Prelude Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Prelude Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Prelude Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -1.77 means the investor is paying $-1.77 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Prelude Therapeutics Inc:

  • The EOD is -1.594. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.772. Based on the earnings, the company is expensive. -2
  • The TTM is -2.003. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.594MRQ-1.772+0.178
MRQ-1.772TTM-2.003+0.231
TTM-2.003YOY-2.538+0.535
TTM-2.0035Y-7.504+5.501
5Y-7.50410Y-7.5040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.594-2.281+0.687
MRQ-1.772-2.599+0.827
TTM-2.003-2.674+0.671
YOY-2.538-4.133+1.595
5Y-7.504-6.258-1.246
10Y-7.504-6.270-1.234
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Prelude Therapeutics Inc:

  • The EOD is -2.134. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.373. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.192. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.134MRQ-2.373+0.239
MRQ-2.373TTM-2.192-0.181
TTM-2.192YOY-3.384+1.192
TTM-2.1925Y-9.609+7.417
5Y-9.60910Y-9.6090.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.134-2.903+0.769
MRQ-2.373-3.323+0.950
TTM-2.192-3.552+1.360
YOY-3.384-5.592+2.208
5Y-9.609-8.378-1.231
10Y-9.609-8.875-0.734
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Prelude Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.99 means the investor is paying $0.99 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Prelude Therapeutics Inc:

  • The EOD is 0.889. Based on the equity, the company is cheap. +2
  • The MRQ is 0.989. Based on the equity, the company is cheap. +2
  • The TTM is 1.096. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.889MRQ0.989-0.100
MRQ0.989TTM1.096-0.107
TTM1.096YOY1.297-0.201
TTM1.0965Y2.671-1.575
5Y2.67110Y2.6710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8891.911-1.022
MRQ0.9892.116-1.127
TTM1.0962.097-1.001
YOY1.2972.885-1.588
5Y2.6713.556-0.885
10Y2.6713.959-1.288
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Prelude Therapeutics Inc.

3.1. Institutions holding Prelude Therapeutics Inc

Institutions are holding 73.735% of the shares of Prelude Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Orbimed Advisors, LLC19.86370.93031090925600
2023-12-31Baker Bros Advisors LP18.43360.49191012382400
2023-12-31Boxer Capital LLC4.67640.54662568287732692.9366
2023-12-31BlackRock Inc1.99490.00011095589271552.5416
2023-12-31T. Rowe Price Associates, Inc.1.89860.00061042737-24121-2.2609
2023-12-31Vanguard Group Inc1.83330.00011006856332503.4151
2023-12-31Massachusetts Financial Services Company0.930.00075107494700.0921
2023-12-31Geode Capital Management, LLC0.63610.0002349367182675.5171
2023-12-31Sio Capital Management, LLC0.58340.3115320394-29606-8.4589
2023-09-30Citadel Advisors Llc0.54640.0002300101263232713.9657
2023-12-31Morgan Stanley - Brokerage Accounts0.54410.00012987965432622.2219
2023-12-31FMR Inc0.48190.0001264687-4866746-94.8419
2023-12-31Renaissance Technologies Corp0.3940.00142164007702655.2657
2023-12-31State Street Corporation0.386402122342502513.3674
2023-12-31TD Asset Management Inc0.29250.000716065200
2023-12-31Bridgeway Capital Management, LLC0.27080.0136148749111800302.5792
2023-09-30Jacobs Levy Equity Management, Inc.0.26210.00261439572747023.582
2023-12-31Goldman Sachs Group Inc0.2530.000113893071242105.2506
2023-12-31Charles Schwab Investment Management Inc0.22710.000112470016691.3566
2023-12-31Northern Trust Corp0.20770.0001114097-1421-1.2301
Total 54.7162.30130050362-4137693-13.8%

3.2. Funds holding Prelude Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31T. Rowe Price Health Sciences1.4040.0224771093-16025-2.0359
2024-02-29Vanguard Total Stock Mkt Idx Inv1.31180.000272042700
2024-03-28iShares Russell 2000 ETF0.65250.00263583541740.0486
2023-12-31Biotech Growth Ord0.63090.353134650000
2024-02-29MFS New Discovery I0.59670.057232769900
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.36080.00081981341190.0601
2024-01-31Fidelity Small Cap Index0.26830.00214736300
2024-03-28iShares Russell 2000 Value ETF0.24680.0051135527-86-0.0634
2023-12-31Bridgeway Ultra-Small Company Market0.2220.280312194985000230.0468
2024-02-29MFS® VIT New Discovery Init0.18660.06031024995740.5632
2024-02-29Fidelity Extended Market Index0.17110.001193995-455-0.4817
2024-03-28Loncar Cancer Immunotherapy ETF0.14821.3422813991410620.9621
2023-12-31TD Health Sciences - I0.14630.02748032600
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.14260.00087830000
2024-03-29Schwab US Small-Cap ETF™0.14060.00217719300
2024-02-29Vanguard Russell 2000 ETF0.09560.00245252242728.8539
2024-02-29Pacific Select Small-Cap Growth I0.07260.062739863-3055-7.1182
2023-12-31T. Rowe Price Health Sciences Port0.0720.02413954800
2023-12-31NT R2000 Value Index Fund - NL0.06980.00433834700
2023-12-31NT R2000 Index Fund - NL0.06930.002238075500.1315
Total 7.00852.25333849113+84674+2.2%

3.3. Insider Transactions

Insiders are holding 6.915% of the shares of Prelude Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-24Krishna VaddiBUY10005.01
2023-05-22Orbimed Advisors LlcBUY8695655.75

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Prelude Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7950.059+1240%-0.523+166%0.254+213%0.254+213%
Book Value Per Share--4.3174.043+7%4.830-11%4.119+5%4.119+5%
Current Ratio--10.79212.686-15%13.117-18%14.321-25%14.321-25%
Debt To Asset Ratio--0.1460.102+44%0.088+65%0.629-77%0.629-77%
Debt To Equity Ratio--0.1710.115+49%0.098+75%0.069+149%0.069+149%
Dividend Per Share----0%-0%-0%-0%
Eps---0.602-0.544-10%-0.609+1%-0.506-16%-0.506-16%
Free Cash Flow Per Share---0.450-0.499+11%-0.457+2%-0.412-8%-0.412-8%
Free Cash Flow To Equity Per Share--0.0100.110-91%-0.453+4793%0.291-97%0.291-97%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.366--------
Intrinsic Value_10Y_min---18.425--------
Intrinsic Value_1Y_max---1.935--------
Intrinsic Value_1Y_min---1.900--------
Intrinsic Value_3Y_max---5.971--------
Intrinsic Value_3Y_min---5.697--------
Intrinsic Value_5Y_max---10.196--------
Intrinsic Value_5Y_min---9.450--------
Market Cap161549952.000-45%234483864.580242168908.863-3%293624008.683-20%689369699.923-66%689369699.923-66%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.889-11%0.9891.096-10%1.297-24%2.671-63%2.671-63%
Pe Ratio-1.594+10%-1.772-2.003+13%-2.538+43%-7.504+323%-7.504+323%
Price Per Share3.840-11%4.2704.390-3%6.193-31%15.275-72%15.275-72%
Price To Free Cash Flow Ratio-2.134+10%-2.373-2.192-8%-3.384+43%-9.609+305%-9.609+305%
Price To Total Gains Ratio4.830-11%5.371-1.689+131%-11.858+321%-24.745+561%-24.745+561%
Quick Ratio--20.18323.740-15%23.354-14%20.482-1%20.482-1%
Return On Assets---0.119-0.120+0%-0.104-13%-0.155+30%-0.155+30%
Return On Equity---0.140-0.134-4%-0.114-18%-0.089-36%-0.089-36%
Total Gains Per Share--0.7950.059+1240%-0.523+166%0.254+213%0.254+213%
Usd Book Value--237090000.000228176000.000+4%228875000.000+4%199330941.176+19%199330941.176+19%
Usd Book Value Change Per Share--0.7950.059+1240%-0.523+166%0.254+213%0.254+213%
Usd Book Value Per Share--4.3174.043+7%4.830-11%4.119+5%4.119+5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.602-0.544-10%-0.609+1%-0.506-16%-0.506-16%
Usd Free Cash Flow---24707000.000-27644000.000+12%-21687000.000-12%-19920235.294-19%-19920235.294-19%
Usd Free Cash Flow Per Share---0.450-0.499+11%-0.457+2%-0.412-8%-0.412-8%
Usd Free Cash Flow To Equity Per Share--0.0100.110-91%-0.453+4793%0.291-97%0.291-97%
Usd Market Cap161549952.000-45%234483864.580242168908.863-3%293624008.683-20%689369699.923-66%689369699.923-66%
Usd Price Per Share3.840-11%4.2704.390-3%6.193-31%15.275-72%15.275-72%
Usd Profit---33075000.000-30108750.000-9%-26106500.000-21%-23736647.059-28%-23736647.059-28%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.7950.059+1240%-0.523+166%0.254+213%0.254+213%
 EOD+2 -6MRQTTM+15 -14YOY+14 -155Y+12 -1710Y+12 -17

4.2. Fundamental Score

Let's check the fundamental score of Prelude Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.594
Price to Book Ratio (EOD)Between0-10.889
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than120.183
Current Ratio (MRQ)Greater than110.792
Debt to Asset Ratio (MRQ)Less than10.146
Debt to Equity Ratio (MRQ)Less than10.171
Return on Equity (MRQ)Greater than0.15-0.140
Return on Assets (MRQ)Greater than0.05-0.119
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Prelude Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.452
Ma 20Greater thanMa 504.484
Ma 50Greater thanMa 1004.441
Ma 100Greater thanMa 2004.003
OpenGreater thanClose3.980
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -1,6921,294-398-313-711106-605828223



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets277,665
Total Liabilities40,575
Total Stockholder Equity237,090
 As reported
Total Liabilities 40,575
Total Stockholder Equity+ 237,090
Total Assets = 277,665

Assets

Total Assets277,665
Total Current Assets235,589
Long-term Assets42,076
Total Current Assets
Cash And Cash Equivalents 25,291
Short-term Investments 207,644
Other Current Assets 2,654
Total Current Assets  (as reported)235,589
Total Current Assets  (calculated)235,589
+/-0
Long-term Assets
Property Plant Equipment 37,737
Long-term Assets Other 295
Long-term Assets  (as reported)42,076
Long-term Assets  (calculated)38,032
+/- 4,044

Liabilities & Shareholders' Equity

Total Current Liabilities21,829
Long-term Liabilities18,746
Total Stockholder Equity237,090
Total Current Liabilities
Short-term Debt 1,481
Accounts payable 4,580
Other Current Liabilities 945
Total Current Liabilities  (as reported)21,829
Total Current Liabilities  (calculated)7,006
+/- 14,823
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt15,407
Long-term Liabilities Other 3,339
Long-term Liabilities  (as reported)18,746
Long-term Liabilities  (calculated)18,746
+/-0
Total Stockholder Equity
Common Stock5
Retained Earnings -456,390
Accumulated Other Comprehensive Income 223
Other Stockholders Equity 693,252
Total Stockholder Equity (as reported)237,090
Total Stockholder Equity (calculated)237,090
+/-0
Other
Capital Stock5
Cash and Short Term Investments 232,935
Common Stock Shares Outstanding 54,914
Current Deferred Revenue14,823
Liabilities and Stockholders Equity 277,665
Net Debt -8,403
Net Invested Capital 237,090
Net Working Capital 213,760
Property Plant and Equipment Gross 41,303
Short Long Term Debt Total 16,888



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-03-31
> Total Assets 
0
0
21,871
0
32,747
239,681
223,590
369,831
349,581
331,217
305,098
280,671
259,055
242,327
220,500
198,320
280,611
258,511
277,665
277,665258,511280,611198,320220,500242,327259,055280,671305,098331,217349,581369,831223,590239,68132,747021,87100
   > Total Current Assets 
0
0
20,224
30,697
30,697
238,061
220,809
365,018
344,575
325,897
295,115
269,972
248,624
226,893
204,380
175,263
260,210
234,916
235,589
235,589234,916260,210175,263204,380226,893248,624269,972295,115325,897344,575365,018220,809238,06130,69730,69720,22400
       Cash And Cash Equivalents 
0
0
18,879
0
29,716
234,792
218,309
362,990
343,119
61,424
31,828
51,634
50,706
52,022
30,605
18,201
26,446
15,896
25,291
25,29115,89626,44618,20130,60552,02250,70651,63431,82861,424343,119362,990218,309234,79229,716018,87900
       Short-term Investments 
0
0
0
0
0
0
0
0
0
259,441
259,405
214,555
195,599
172,021
171,123
154,054
228,543
214,610
207,644
207,644214,610228,543154,054171,123172,021195,599214,555259,405259,441000000000
       Other Current Assets 
0
0
1,345
0
981
3,269
2,500
2,028
1,456
5,032
263,287
3,783
2,319
2,850
2,652
3,008
5,221
4,410
2,654
2,6544,4105,2213,0082,6522,8502,3193,783263,2875,0321,4562,0282,5003,26998101,34500
   > Long-term Assets 
0
0
1,647
0
2,050
1,620
2,781
4,813
5,006
5,320
9,983
10,699
10,431
15,434
16,120
23,057
20,401
23,595
42,076
42,07623,59520,40123,05716,12015,43410,43110,6999,9835,3205,0064,8132,7811,6202,05001,64700
       Property Plant Equipment 
0
0
1,647
1,575
1,575
1,620
2,480
4,813
5,006
5,320
5,636
6,346
6,078
6,464
6,700
6,731
7,000
7,082
37,737
37,7377,0827,0006,7316,7006,4646,0786,3465,6365,3205,0064,8132,4801,6201,5751,5751,64700
       Other Assets 
0
0
0
475
475
0
301
0
0
0
4,347
4,353
4,353
8,970
9,420
16,326
13,401
0
0
0013,40116,3269,4208,9704,3534,3534,3470003010475475000
> Total Liabilities 
0
0
71,283
0
102,058
11,374
11,407
13,264
15,220
19,975
19,201
18,859
18,211
24,920
25,063
23,023
18,551
20,254
40,575
40,57520,25418,55123,02325,06324,92018,21118,85919,20119,97515,22013,26411,40711,374102,058071,28300
   > Total Current Liabilities 
0
0
4,835
5,639
5,639
11,359
11,375
12,424
14,677
19,663
19,201
16,069
15,811
21,560
21,702
19,662
15,190
16,893
21,829
21,82916,89315,19019,66221,70221,56015,81116,06919,20119,66314,67712,42411,37511,3595,6395,6394,83500
       Short-term Debt 
0
0
258
0
67
0
0
1,403
1,403
1,836
1,740
1,859
1,822
1,388
1,832
1,390
938
475
1,481
1,4814759381,3901,8321,3881,8221,8591,7401,8361,4031,4030067025800
       Accounts payable 
0
0
1,974
3,471
3,471
5,074
3,920
4,842
6,844
11,062
7,840
7,390
6,273
10,250
6,777
7,082
5,585
5,170
4,580
4,5805,1705,5857,0826,77710,2506,2737,3907,84011,0626,8444,8423,9205,0743,4713,4711,97400
       Other Current Liabilities 
0
0
2,861
0
2,168
6,285
7,455
6,179
6,430
6,765
9,621
6,820
7,716
9,922
13,093
11,190
8,667
11,248
945
94511,2488,66711,19013,0939,9227,7166,8209,6216,7656,4306,1797,4556,2852,16802,86100
   > Long-term Liabilities 
0
0
66,448
0
96,419
15
32
840
543
312
9,580
2,790
2,400
3,360
3,361
3,361
3,361
3,361
18,746
18,7463,3613,3613,3613,3613,3602,4002,7909,580312543840321596,419066,44800
       Other Liabilities 
0
0
0
34
34
15
32
0
0
0
0
2,400
2,400
3,360
3,361
3,361
3,361
0
0
003,3613,3613,3613,3602,4002,400000032153434000
       Deferred Long Term Liability 
0
0
0
475
475
0
301
0
0
0
0
0
0
0
0
0
0
0
0
0000000000003010475475000
> Total Stockholder Equity
0
0
-49,412
0
-69,311
228,307
212,183
356,567
334,361
311,242
285,897
261,812
240,844
217,407
195,437
175,297
262,060
238,257
237,090
237,090238,257262,060175,297195,437217,407240,844261,812285,897311,242334,361356,567212,183228,307-69,3110-49,41200
   Common Stock
0
0
0
0
0
4
4
5
5
5
5
5
5
5
5
5
5
5
5
5555555555554400000
   Retained Earnings Total Equity0000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-556
0
0
-239,681
0
0
0
-176
-711
-2,313
-2,294
-2,363
-1,692
-398
-711
-605
223
223-605-711-398-1,692-2,363-2,294-2,313-711-176000-239,68100-55600
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
1,641
0
2,105
316,479
319,605
485,288
489,947
497,691
505,723
512,705
519,092
525,682
531,682
537,966
655,473
662,172
693,252
693,252662,172655,473537,966531,682525,682519,092512,705505,723497,691489,947485,288319,605316,4792,10501,64100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,169
Gross Profit-1,169-1,169
 
Operating Income (+$)
Gross Profit-1,169
Operating Expense-131,108
Operating Income-132,277-132,277
 
Operating Expense (+$)
Research Development103,393
Selling General Administrative28,884
Selling And Marketing Expenses1,169
Operating Expense131,108133,446
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-132,277
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-121,832-142,722
EBIT - interestExpense = -132,277
-121,832
-121,832
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-132,277-121,832
Earnings Before Interest and Taxes (EBITDA)-131,108
 
After tax Income (+$)
Income Before Tax-121,832
Tax Provision-0
Net Income From Continuing Ops-117,398-121,832
Net Income-121,832
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses132,277
Total Other Income/Expenses Net10,4450
 

Technical Analysis of Prelude Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Prelude Therapeutics Inc. The general trend of Prelude Therapeutics Inc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Prelude Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Prelude Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.41 < 5.83 < 6.025.

The bearish price targets are: 3.42 > 2.62 > 1.66.

Tweet this
Prelude Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Prelude Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Prelude Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Prelude Therapeutics Inc. The current macd is -0.18301603.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Prelude Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Prelude Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Prelude Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Prelude Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartPrelude Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Prelude Therapeutics Inc. The current adx is 25.51.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Prelude Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Prelude Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Prelude Therapeutics Inc. The current sar is 4.93795635.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Prelude Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Prelude Therapeutics Inc. The current rsi is 40.45. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Prelude Therapeutics Inc Daily Relative Strength Index (RSI) ChartPrelude Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Prelude Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Prelude Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Prelude Therapeutics Inc Daily Stochastic Oscillator ChartPrelude Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Prelude Therapeutics Inc. The current cci is -81.65802202.

Prelude Therapeutics Inc Daily Commodity Channel Index (CCI) ChartPrelude Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Prelude Therapeutics Inc. The current cmo is -25.29184107.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Prelude Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartPrelude Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Prelude Therapeutics Inc. The current willr is -82.57261411.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Prelude Therapeutics Inc Daily Williams %R ChartPrelude Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Prelude Therapeutics Inc.

Prelude Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Prelude Therapeutics Inc. The current atr is 0.38095174.

Prelude Therapeutics Inc Daily Average True Range (ATR) ChartPrelude Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Prelude Therapeutics Inc. The current obv is 3,524,176.

Prelude Therapeutics Inc Daily On-Balance Volume (OBV) ChartPrelude Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Prelude Therapeutics Inc. The current mfi is 63.86.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Prelude Therapeutics Inc Daily Money Flow Index (MFI) ChartPrelude Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Prelude Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Prelude Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Prelude Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.452
Ma 20Greater thanMa 504.484
Ma 50Greater thanMa 1004.441
Ma 100Greater thanMa 2004.003
OpenGreater thanClose3.980
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Prelude Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Prelude Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Prelude Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Prelude Therapeutics Inc

I send you an email if I find something interesting about Prelude Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Prelude Therapeutics Inc.

Receive notifications about Prelude Therapeutics Inc in your mailbox!